Seeking Alpha ... patents in the transrenal space. Unlike pharmaceutical companies that must demonstrate not only efficacy but also safety in time and money intensive clinical trials, Trovagene's position as a non-invasive diagnostic company only needs to ...
Business Wire (press release) Fitch believes that Pfizer will continue to generate superior cash flow despite the top-line pressures from key drug patent exclusivity lapses and expects that operating cash flow will remain above $18 billion through the intermediate -term. Pfizer ... 更多 »
Investorplace.com Click to EnlargeAcorda Pharmaceuticals (ACOR) is a commercial-stage biotech/ pharmaceutical company that develops drugs for neurological conditions, and looking at the chart, the company's stock is doing quite well, at least in the short term. The price ...
San Francisco Chronicle Meda AB slid 6.1 percent in Stockholm after the maker of the Dymista allergy medicine said it's not in talks to merge with another pharmaceutical company. The S&P 500 dropped 0.6 percent yesterday. The 135,000 increase in employment followed a revised ... 更多 »
4-traders (press release) With business operations in nine countries, ACETO and its Rising Pharmaceuticals subsidiary sells over 1,200 products used as RX generic drugs or raw materials in the pharmaceutical , nutraceutical, agricultural, coatings and industrial chemical industries.
NASDAQ With business operations in nine countries, ACETO and its Rising Pharmaceuticals subsidiary sells over 1,200 products used as RX generic drugs or raw materials in the pharmaceutical , nutraceutical, agricultural, coatings and industrial chemical industries. and more »
